Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

NCT03375320 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03375320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03375320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 26, 2018
Completion date
September 1, 2027
Enrollment
298 (actual)
Sites
432

Conditions

As the registry lists them; a condition with its own page is linked.

functioning pancreatic neuroendocrine tumor, intermediate grade lung neuroendocrine neoplasm, locally advanced digestive system neuroendocrine neoplasm, locally advanced digestive system neuroendocrine tumor g1, locally advanced lung neuroendocrine neoplasm, locally advanced pancreatic neuroendocrine tumor, locally advanced unresectable digestive system neuroendocrine neoplasm, low grade lung neuroendocrine neoplasm, lung neuroendocrine tumor, lung neuroendocrine tumor g2, metastatic digestive system neuroendocrine neoplasm, metastatic digestive system neuroendocrine tumor g1, metastatic lung neuroendocrine neoplasm, metastatic lung neuroendocrine tumor, metastatic pancreatic neuroendocrine neoplasm, metastatic pancreatic neuroendocrine tumor, metastatic thymus neuroendocrine neoplasm, neuroendocrine neoplasm, neuroendocrine tumor, neuroendocrine tumor g2, non-functioning pancreatic neuroendocrine tumor, pancreatic serotonin-producing neuroendocrine tumor, thymus neuroendocrine tumor, unresectable digestive system neuroendocrine neoplasm, unresectable digestive system neuroendocrine tumor g1, unresectable lung neuroendocrine neoplasm, unresectable pancreatic neuroendocrine neoplasm, unresectable thymus neuroendocrine neoplasm